Buscar
Castle Biosciences Inc
CSTLAñadir a la lista de seguimiento
28.090USD
+1.300+4.85%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
856.98MCap. mercado
PérdidaP/E TTM
Más Datos de Castle Biosciences Inc Compañía
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
Información de Castle Biosciences Inc
Símbolo de cotizaciónCSTL
Nombre de la empresaCastle Biosciences Inc
Fecha de salida a bolsaJul 25, 2019
Director ejecutivoMaetzold (Derek J)
Número de empleados761
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 25
Dirección505 S Friendswood Drive
CiudadFRIENDSWOOD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal77546
Teléfono18667889007
Sitio Webhttps://castlebiosciences.com/
Símbolo de cotizaciónCSTL
Fecha de salida a bolsaJul 25, 2019
Director ejecutivoMaetzold (Derek J)
Ejecutivos de Castle Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
119.13K
-7.21%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
98.03K
+11.43%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
40.92K
+33.40%
Mr. Miles D. Harrison
Mr. Miles D. Harrison
Independent Director
Independent Director
35.63K
+38.36%
Mr. Rodney Cotton
Mr. Rodney Cotton
Independent Director
Independent Director
33.00K
+41.42%
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Frank Stokes
Mr. Frank Stokes
Chief Financial Officer
Chief Financial Officer
--
--
Mr. G. Bradley Cole
Mr. G. Bradley Cole
Independent Director
Independent Director
--
--
Ms. Kimberlee S. Caple
Ms. Kimberlee S. Caple
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
119.13K
-7.21%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
98.03K
+11.43%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
40.92K
+33.40%
Mr. Miles D. Harrison
Mr. Miles D. Harrison
Independent Director
Independent Director
35.63K
+38.36%
Mr. Rodney Cotton
Mr. Rodney Cotton
Independent Director
Independent Director
33.00K
+41.42%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Castle Biosciences Inc?
Los cinco principales accionistas de Castle Biosciences Inc son: Mr. Derek J. Maetzold
¿Cuántas instituciones poseen acciones de Castle Biosciences Inc (CSTL)?
A fecha de 2026Q1, 413 instituciones poseen acciones de Castle Biosciences Inc, con un valor de mercado combinado de aproximadamente 27.62M, lo que representa el 91.06% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1802863.00.